Pyxis Oncology, Inc. Current Assets
Pyxis Oncology, Inc. (PYXS) had Current Assets of $36.73 million as of 2026-06-30, per its 10-Q filed 2026-08-13.
Financial Statements › Balance Sheet › Assets › Assets, Current
us-gaap:AssetsCurrent · last filed 2026-08-13
- 2026-06-30: Assets, Current $36.73M.
- 2026-03-31: Assets, Current $45.57M.
- 2025-12-31: Assets, Current $72.11M.
- 2025-09-30: Assets, Current $83.07M.
| Period end | Assets, Current |
|---|---|
| 2026-06-30 | $36.73M 10-Q · filed 2026-08-13 |
| 2026-03-31 | $45.57M 10-Q · filed 2026-05-14 |
| 2025-12-31 | $72.11M 10-Q · filed 2026-08-13 |
| 2025-09-30 | $83.07M 10-Q · filed 2025-11-03 |
| 2025-06-30 | $99.96M 10-Q · filed 2025-08-14 |
| 2025-03-31 | $111.87M 10-Q · filed 2025-05-15 |
| 2024-12-31 | $132.44M 10-K · filed 2026-03-23 |
| 2024-09-30 | $148.87M 10-Q · filed 2024-11-12 |
| 2024-06-30 | $161.04M 10-Q · filed 2024-08-14 |
| 2024-03-31 | $172.38M 10-Q · filed 2024-05-14 |
| 2023-12-31 | $124.60M 10-K · filed 2025-03-18 |
| 2023-09-30 | $139.09M 10-Q · filed 2023-11-07 |
| 2023-06-30 | $149.30M 10-Q · filed 2023-08-11 |
| 2023-03-31 | $156.18M 10-Q · filed 2023-05-11 |
| 2022-12-31 | $186.61M 10-K · filed 2024-03-21 |
| 2022-09-30 | $202.81M 10-Q · filed 2022-11-01 |
| 2022-06-30 | $226.59M 10-Q · filed 2022-08-15 |
| 2022-03-31 | $251.26M 10-Q · filed 2022-05-13 |
| 2021-12-31 | $278.67M 10-K · filed 2023-03-22 |
| 2021-09-30 | $134.34M 10-Q · filed 2021-11-15 |
| 2020-12-31 | $8.10M 10-K · filed 2022-03-29 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Entrada Therapeutics, Inc. (TRDA) | United States | $0.243B | -1.73 |
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |